Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$4.15 USD
+0.06 (1.47%)
Updated Jul 26, 2024 04:00 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALDX 4.15 +0.06(1.47%)
Will ALDX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALDX
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
ALDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Other News for ALDX
Commit To Purchase Aldeyra Therapeutics At $2.50, Earn 16.6% Annualized Using Options
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
Aldeyra announces advancement of new RASP modulators, preclinical data
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aldeyra Therapeutics (ALDX), Cardinal Health (CAH) and Roche Holding AG (OtherRHHVF)
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease